Pontifax Management 4 G.P. (2015) Ltd. - Apr 17, 2025 SCHEDULE 13D/A Report for Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share (KROS)

Filing Manager
Pontifax Management 4 G.P. (2015) Ltd.
Reporting Manager
Pontifax Management 4 GP (2015) Ltd.
Security
Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share
Symbol
KROS
Shares outstanding
40.6M shares
Disclosed Ownership
4.79M shares
Ownership
11.8%
Form type
SCHEDULE 13D/A
Date filed
4/18/2025, 05:10 PM
Date of event
Apr 17, 2025
Next filing
Oct 16, 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Pontifax Management 4 GP (2015) Ltd. 11.8% 4.79M 0 4.79M /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer 0001726334
Pontifax (Israel) IV, L.P. 5.6% 2.28M 0 2.28M /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax (Cayman) IV, L.P. 2.8% 1.12M 0 1.12M /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax (China) IV, L.P. 3% 1.23M 0 1.23M /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax Late Stage Fund L.P. 0.4% 155K 0 155K /s/ Asaf Shinar Asaf Shinar, Chief Financial Officer
Pontifax Late Stage GP Ltd. 0.4% 155K 0 155K /s/ Asaf Shinar Asaf Shinar, Chief Financial Officer